Literature DB >> 3938397

Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells.

M A Blankenstein, M S Henkelman, J G Klijn.   

Abstract

The effect of the LHRH agonist Buserelin on the MCF-7 human breast cancer cell line was studied. Cells were cultured in medium containing 10% untreated foetal calf serum or 10% steroid-depleted serum. In both media the DNA and protein content of cultures kept for 3-5 days in the presence of 80-800 nM Buserelin and 1 nM oestradiol were 8-27% lower than those of flasks cultured in the presence of oestradiol alone (P less than 0.05). LHRH itself (400 nM) also displayed an antiproliferative effect on the MCF-7 cultures. At an equimolar concentration, the LHRH antagonist ORG 30093D abolished the antiproliferative effect of Buserelin. MCF-7 cells did not specifically take up radioiodinated LHRH. Our data are the first to indicate that LHRH analogues may inhibit the growth of MCF-7 cells to a limited extent. The antitumour activity of these compounds in vivo may, then, be due to the main pituitary and gonadal effects, resulting in a decrease of the concentration of oestrogen in the circulation and, in addition, a direct effect at the target cell level.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3938397     DOI: 10.1016/0277-5379(85)90244-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  17 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Influence on antiproliferative activity of structural modification and conjugation of gonadotropin-releasing hormone (GnRH) analogues.

Authors:  A Kálnay; I Pályi; B Vincze; R Mihalik; I Mezõ; J Pató; J Seprõdi; S Lovas; R F Murphy
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

3.  Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.

Authors:  T Janáky; A Juhász; Z Rékási; P Serfözö; J Pinski; L Bokser; G Srkalovic; S Milovanovic; T W Redding; G Halmos
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

4.  Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters.

Authors:  K H Baumann; L Kiesel; M Kaufmann; G Bastert; B Runnebaum
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.

Authors:  S R Milovanovic; S Radulovic; A V Schally
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 6.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

7.  Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells.

Authors:  G Sica; F Iacopino; G Robustelli della Cuna; P Marchetti; L Marini
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.

Authors:  T Yano; J Pinski; S Radulovic; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

9.  Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells.

Authors:  B Szende; G Srkalovic; J Timar; J J Mulchahey; J D Neill; K Lapis; A Csikos; K Szepeshazi; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

10.  Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.

Authors:  S R Milovanovic; E Monje; K Szepeshazi; S Radulovic; A Schally
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.